Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220358 · ClinicalTrials.gov registry record · Phase 4
Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study
A Phase 4 study of HIV-1-infection, sponsored by Orlando Immunology Center.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05220358 is a Phase 4 study of HIV-1-infection that is active but no longer recruiting, run by Orlando Immunology Center. The registered enrollment target is 25 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05220358, a Phase 4 study of HIV-1-infection, is active but no longer recruiting, sponsored by Orlando Immunology Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic parameters such as CD4 T-cell count, CD4 T-cell percentage and CD4/CD8 ratio
Conditions Studied
Interventions
- DRUG Fostemsavir 600 MG [Rukobia]
Study Locations (1)
Florida
- Orlando Immunology Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-02-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220358
The ClinicalTrials.gov registry entry for NCT05220358 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (93% lower). The listed sponsor is Orlando Immunology Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 1 intervention - of which Fostemsavir 600 MG [Rukobia] is the first listed.
NCT05220358 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05220358 about?
NCT05220358 is a clinical study titled "Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study". The RECOVER study is a self-controlled case series to evaluate whether the addition of Fostemsavir (Rukobia) to a stable HIV regimen in virologically suppressed patients living with HIV who never experience optimal CD4 T-cell count recovery can result in meaningful increases in different immunologic...
What is the current status of trial NCT05220358?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2022-06-15. Estimated completion is 2026-02-13.
What conditions does trial NCT05220358 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05220358?
The interventions under investigation include: Fostemsavir 600 MG [Rukobia] (DRUG).
Who is sponsoring clinical trial NCT05220358?
This trial is sponsored by Orlando Immunology Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220358 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)
COMPLETED · Phase 4
-
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
COMPLETED · Phase 4
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
RECRUITING · NA
-
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.